Bright Minds

3 days ago

William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area

Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into radiopharmaceutical, and discusses AASLD, Seagen, and Icosavax.

SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

Nov 22

Bright Minds

SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

Simeon George talks about his firm's philosophy, advice for biotech entrepreneurs, and discusses a busy few weeks of news.

Sofinnova Investments' Jakob Dupont on the private markets in biotech

Nov 20

Bright Minds

Sofinnova Investments' Jakob Dupont on the private markets in biotech

Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND.

BMO's Evan Seigerman joins Analyst Thursdays from London

Nov 16

Bright Minds

BMO's Evan Seigerman joins Analyst Thursdays from London

Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.

Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays

Nov 9

Bright Minds

Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays

Paul Matteis comments on Biogen and Vertex earnings, discusses recent news on BioMarin and Sage.

PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria

Nov 7

Bright Minds

PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria

Amanda Burkhardt describes how phages selectively target bacteria of interest and how PHIOGEN's platform is designed for broad spectrum.

An AI expert describes how machine learning is changing drug development

Nov 7

Bright Minds

An AI expert describes how machine learning is changing drug development

Angela Holmes explains how her company uses computational power to help companies with drug development.

The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

Nov 7

Bright Minds

The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

Raphaël Ognar discusses the results we have seen in the NK space over recent years.

Tvardi Threrapeutics' CEO on targeting STAT3

Nov 7

Bright Minds

Tvardi Threrapeutics' CEO on targeting STAT3

Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3.

Everything drug developers need to know about CPRIT oncology grants

Nov 7

Bright Minds

Everything drug developers need to know about CPRIT oncology grants

CPRIT Deputy Executive Officer and General Counsel Kristen Doyle explains the details of this Texas cancer research funding program.

UTMB's President discusses his institution, and comments on the chronic kidney disease field

Nov 7

Bright Minds

UTMB's President discusses his institution, and comments on the chronic kidney disease field

Jochen Reiser talks about the reach of UTMB and the science happening in Galveston, and highlights immunology approaches to kidney disease.

The director of Rice's Biotech Launchpad describes technologies that are being turned into companies

Nov 7

Bright Minds

The director of Rice's Biotech Launchpad describes technologies that are being turned into companies

Omid Veiseh explains the idea behind Rice's Biotech Launchpad, describes the cytokine company Avenge Bio, and talks about other technologies

Texas Medical Center's CEO talks about Houston's new TMC Helix Park

Nov 7

Bright Minds

Texas Medical Center's CEO talks about Houston's new TMC Helix Park

Bill McKeon describes TMC's news campus that is focused on translational research.

BioHouston CEO Ann Tanabe kicks off the 2023 Texas Life Science Forum

Nov 7

Bright Minds

BioHouston CEO Ann Tanabe kicks off the 2023 Texas Life Science Forum

Ann Tanabe gives a preview of the 12th annual Texas Life Science Forum from Houston.

Y-Trap's Rishi Bedi on how predictive & generative AI are changing drug development

Nov 5

Bright Minds

Y-Trap's Rishi Bedi on how predictive & generative AI are changing drug development

Rishi Bedi explains how AI might be impacting protein design, genetic medicine, immuno-oncology and more in the future.

Dan Chen's closing takeaways from #SITC23

Nov 5

Bright Minds

Dan Chen's closing takeaways from #SITC23

Dr. Chen talks about emerging technologies he is excited about such logic gating, AI, and multi-specific nanobots.

Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23

Nov 4

Bright Minds

Aleta Biotherapeutics' Paul Rennert on what he sees is working, and what isn't, at #SITC23

Paul Rennert gives an update on Aleta, and summarizes data at #SITC23 from the IO 2.0, cytokine, TGF beta, Treg, lymphoid, and CAR-T spaces.

The CEO of Marengo Therapeutics talks about his company's focus on activating and expanding T-cells

Nov 4

Bright Minds

The CEO of Marengo Therapeutics talks about his company's focus on activating and expanding T-cells

Zen Su gives an overview Marengo, his view of #SITC23, and SITC's new biotech initiative.

Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23

Nov 4

Bright Minds

Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23

John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.

SITC Biotech Strategic Initiative Co-Chair Kristen Hege on the IO field

Nov 3

Bright Minds

SITC Biotech Strategic Initiative Co-Chair Kristen Hege on the IO field

Dr. Hege discusses the latest in cell therapy, new modalities, and a biotech initiative that SITC is launching.

Home

BiotechTV U

Company News

Bright Minds

Tech + Tours

Follow BiotechTV

Sponsors

Popular

Get in Touch

Advertise:

News coverage opportunities:

Advertise@BiotechTV.com

MediaOppty@BiotechTV.com

General equiries and feedback:

BiotechTV U:

Info@BiotechTV.com

Universities@BiotechTV.com

Contributors

Brad Loncar

Founder

Join our mail list

Disclosures & Policies